Tokio Marine (TKOMY) Upgraded to Strong Buy: Here's Why
Investors might want to bet on Tokio Marine Holdings Inc. (TKOMY), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.
A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.
The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.
As such, the Zacks rating upgrade for Tokio Marine is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price.
The change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. The influence of institutional investors has a partial contribution to this relationship, as these big professionals use earnings and earnings estimates to calculate the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock.
For Tokio Marine, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher.
Empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .
For the fiscal year ending March 2026, this company is expected to earn $4.04 per share, which is unchanged compared with the year-ago reported number.
Analysts have been steadily raising their estimates for Tokio Marine. Over the past three months, the Zacks Consensus Estimate for the company has increased 5.2%.
Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.
You can learn more about the Zacks Rank here >>>
The upgrade of Tokio Marine to a Zacks Rank #1 positions it in the top 5% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Tokio Marine Holdings Inc. (TKOMY) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Entrepreneur
an hour ago
- Entrepreneur
Several Tailwinds Powering ServiceNow India's Growth: Sumeet Mathur
Over the past decade, the company's presence in India has transformed into a microcosm of its global organization. The India team has tripled in size in just two years, with 1 in 3 ServiceNow engineers globally now based in India. You're reading Entrepreneur India, an international franchise of Entrepreneur Media. Tech 25: Sumeet Mathur, SVP and MD, ServiceNow India ServiceNow was founded in 2004 by Fred Luddy with a simple yet powerful vision: to make work easier for people by creating a cloud-based platform that could streamline and automate routine IT service management tasks. It was incorporated as Glidesoft, Inc. in 2003, but formally established and became ServiceNow in 2004. Initially focused on IT Service Management (ITSM), the company offered a modern alternative to legacy systems, enabling faster, more efficient service delivery. Over the years, ServiceNow has evolved into a leading enterprise platform, expanding its capabilities beyond IT to include workflows for customer service, HR, security, operations, and more. Globally, ServiceNow caters to 85 per cent of Fortune 500 companies and closed 2024 with USD 10.27 billion in revenue, marking 19 per cent year-on-year growth. India has played an increasingly pivotal role in ServiceNow's global growth story under the leadership of Sumeet Mathur, SVP and MD, ServiceNow India. Over the past decade, the company's presence in India has transformed into a microcosm of its global organization. The India team has tripled in size in just two years, with 1 in 3 ServiceNow engineers globally now based in India. Engineers and developers make up 85 per cent of the India workforce, which now accounts for over 20 per cent of the company's global headcount. The Hyderabad office has become its largest employee hub worldwide. ServiceNow India supports many of the country's top technology providers and is trusted by four out of India's top five banks. Recently, ServiceNow has introduced new AI innovations that drive real productivity gains. Unlike many AI agents trapped in isolated silos – like chatbots limited to CRM apps – ServiceNow believes its AI agents are deeply integrated across the entire enterprise. Mathur believes ServiceNow stays ahead of the curve by consistently innovating its platform, investing in AI and automation, and staying closely aligned with customer needs. "Central to this strategy is putting AI to work for people – using generative AI and machine learning to make work more intuitive, intelligent, and efficient across the enterprise," he says. In addition to a favourable technology environment, there are several tailwinds powering ServiceNow India's growth. With over 1,600 global capability centres (GCCs), the country is home to some of the most digitally mature hubs driving cutting-edge innovations – areas where ServiceNow is uniquely positioned to lead. "India is undergoing a remarkable transformation – from a labour-driven economy to an AI-first powerhouse – and is poised to become the world's third-largest economy by 2027. We are seeing strong momentum, with four of India's five largest banks leveraging our platform and an 80 per cent growth in our partner ecosystem over the past year. The next frontier is manufacturing, where we aim to drive global competitiveness through digital transformation. At the same time, India is emerging as a key player in the global shift toward Agentic AI. ServiceNow is uniquely positioned to lead this evolution," says Mathur. Company Facts: Year of Inception: 2004 Current Employee Count: 26,698 employees globally as of Q1 2025; 20% of global workforce based in India Major Clients: LTIMindtree, Wipro, Infosys, Poonawalla Fincorp, Mindsprint Any IP developed/patented: 2,247 total patents (granted) assets globally
Yahoo
3 hours ago
- Yahoo
Paychex shares recoup a bit; CEO comments about economy; analysts weigh in
Paychex shares recoup a bit; CEO comments about economy; analysts weigh in originally appeared on TheStreet. At Paychex () there's no such thing as a free toaster. That may sound confusing, but President and Chief Executive John Gibson brought it all together during the payroll- and human-resources-services provider's fiscal fourth-quarter earnings call. 💵💰Don't miss the move: Subscribe to TheStreet's free daily newsletter 💰 "I've said it multiple times: We're going to continue to be disciplined about growth," he told analysts on June 25. "That client number can be whatever you want it to be if you're willing to spend more than the lifetime value of the customer to acquire the customer.""And we're not going to go crazy with promotions," he added. "We're not going to give away toasters and other gadgets to try to accelerate a number that you're going to add a client that you have to service. We're going to continue to be aggressive in driving client growth, but we're going to continue to also be Paychex." Gibson commented on a tough day for Paychex, which was the worst-performing stock in the S&P 500 after the company missed Wall Street's sales expectations and trimmed its full-year forecasts. The company in April closed the acquisition of human-capital-management-software maker Paycor for $4.1 billion cash. Gibson told analysts that "all of the changes that we wanted to make we made in the fourth quarter." "And we made a strategic decision that given the distractions that were already out there, with Liberation Day and everything else in the marketplace, that now was the time to go ahead and move as quickly as we could to get everything done," he said. April 2 was what President Donald Trump called Liberation Day, his reveal of his tariff policy agenda.."We certainly could have done it at a different pace that would have dragged it potentially into the first quarter of this fiscal year, but we made an election to get all of it out of the way," he explained. Turning to the economy, Gibson said the company was seeing a mix of both optimism and uncertainty within the market and its client base. "Many businesses are frozen as they wait for more clarity about a number of macro issues such as tariffs, inflation and taxes," he said. "The hard data continues to indicate that small businesses remain fundamentally healthy despite the headlines." A Paychex small business report showed stable employment levels with moderation in hourly wage inflation in recent months. "Our data does not currently show any signs of recession," the executive said. "We also see our interactions in the market that the uncertainty is prompting businesses to exercise caution when making decisions and being cautious about how much they are spending on products and services." He noted that Paychex in fiscal Q4 had also seen bankruptcies and financial distress increase in the market and in its client base. "Many businesses, I think, on the edge of failure may have decided not to fight that new headwinds they see in front of them," he said. "We also saw losses due to increases in business combinations and mergers increase more than typical." "We will continue to monitor the hard data and trends in the market and take the appropriate steps to position Paychex to win in any market conditions," he said. After the drop on June 25, Paychex shares were off 1.6% in 2025 and up 17.5% from a year earlier. At last check they were up 1.6% at $140.12. Following the Paychex earnings release, UBS cut its price target on Paychex to $145 from $155 and affirmed a neutral rating on the shares, according the The Fly. A "lackluster" fiscal 2026 should keep Paychex stock range-bound, UBS said. Stifel lowered its price target on Paychex to $152 from $156, while maintaining a hold rating, stating that "confusion" surrounding fiscal 2026 guidance is "more impactful than any fundamental shifts." Last year's fiscal Q4 annual price increase was instituted earlier than historical practice, which distorts the comparisons, Stifel said. The investment firm said that management reported some weakening data points, but Stifel views the installed base as stable and see no signs of pending pared its target on Paychex to $140 from $155 and also affirmed a hold rating. The Q4 results disappointed largely due to slower growth in organic Management Solutions revenue. Management cited multiple reasons including distractions related to integrating Paycor, Jefferies said. However, the investment firm added, while the shares might drop further, the large post-print move and easier setup likely creates a floor against material near-term shares recoup a bit; CEO comments about economy; analysts weigh in first appeared on TheStreet on Jun 26, 2025 This story was originally reported by TheStreet on Jun 26, 2025, where it first appeared. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
SINOVAC Board of Directors Prevails Against Advantech/Prime's Lawsuit in Hong Kong
Hong Kong Court denies Advantech/Prime's petition for Interim Relief Clears another legal hurdle for distribution of the US$55.00 per common share special cash dividend declared by the current SINOVAC Board to be paid on or about July 7, 2025 BEIJING, June 27, 2025--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced it has prevailed against the latest lawsuit filed by Advantech/Prime Success ("Advantech/Prime") in Hong Kong. This result follows Advantech/Prime's recently failed petition in New York last week, which was a repeated attempt by the purported PIPE Investors to block or delay a hearing for interim relief sought by the Company et al at the Antiguan High Court and to interfere with the payment of the US$55.00 per common share special cash dividend to valid shareholders of the Company as declared by the current SINOVAC Board. On June 24, Advantech/Prime delivered via email an ex parte Summons to SINOVAC, 1Globe Capital LLC ("1Globe") and OrbiMed Partners Master Fund Limited ("OrbiMed") for an "interim-interim" injunction application (the "Application"). Vivo Capital also sought to join the Application on June 26. After the emergent hearing at the High Court of Hong Kong on June 27, the court refused to grant any of the relief sought in the Summons. Among other things, the judge also criticized Advantech/Prime for: Failing to comply with the duty of full and frank disclosure in the Application; and The alleged urgency of the Application being self-induced by Advantech/Prime. The court also ordered that legal costs incurred in the Application by SINOVAC, 1Globe and OrbiMed be compensated by Advantech/Prime, with quantum to be assessed. Advantech/Prime's continued multi-jurisdictional lawfare is intended to interfere with rightful dividend payments to SINOVAC's valid shareholders and distract from its long history of self-serving schemes. These schemes include: Privatization attempt at a below-market price in 2016; Invalid PIPE transaction at a below-market price in 2018, which materially diluted SINOVAC shareholders and was made at a time when the Company did not need the capital; US$7.5 million debt investment into Sinovac Life Sciences Co., Ltd. ("SLS"), a wholly owned subsidiary of SINOVAC, in exchange for a 7.5% equity interest in SLS in 2020, at a time when the Company did not need the capital and which has resulted in over US$500 million of distributions made to Advantech/Prime to date while common shareholders have received nothing; and Baseless and wasteful legal action in 2025 to interfere with the dividend payment unless Advantech/Prime is able to double dip on dividends already received from SLS. The current SINOVAC Board remains committed to its mission of restoring fairness, delivering value, and protecting the rights of all valid shareholders. Your Vote is Important Your vote on or before July 8 will be about the future of SINOVAC, your receipt of your make-whole dividend payments in the near-term, and the long-term value of your investment. We urge you to keep SINOVAC's Board in place and vote on the WHITE proxy card "AGAINST" Proposal 1 to remove the current Board and "AGAINST" Proposal 2 to appoint the Reconstituted Imposter Former Board Slate. Your vote is critical to ensuring that SINOVAC remains on the path to stability, growth, and value creation for all shareholders. DISCARD any items you received asking you to vote for the Reconstituted Imposter Former Board Slate. If you have already voted for the Reconstituted Imposter Former Board Slate, you can subsequently revoke it by using the WHITE proxy card or WHITE voting instruction form to vote. Only your latest-dated vote will count! If you have questions about how your vote can be counted, please contact our proxy solicitor, Georgeson LLC, toll free at (844) 568-1506 in the U.S. and (646) 543-1968 outside the U.S. or via email at SinovacSpecialMeeting@ About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations. Important Additional Information and Where to Find It In connection with SINOVAC's Special Meeting, SINOVAC has filed with the U.S. Securities and Exchange Commission ("SEC") and mailed to shareholders of record entitled to vote at the Special Meeting a definitive proxy statement and other documents, including a WHITE proxy card. SHAREHOLDERS ARE ENCOURAGED TO READ THE PROXY STATEMENT AND ALL OTHER RELEVANT DOCUMENTS WHEN FILED WITH THE SEC AND WHEN THEY BECOME AVAILABLE BECAUSE THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION. Investors and other interested parties will be able to obtain the documents free of charge at the SEC's website, or from SINOVAC at its website: You may also obtain copies of SINOVAC's definitive proxy statement and other documents, free of charge, by contacting SINOVAC's Investor Relations Department at ir@ Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. Such statements are based upon current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's or Board's control, which may cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company and Board do not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law. View source version on Contacts Investor and Media Contact FGS GlobalSinovac@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
